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Toxoplasmosis is the most frequent cause of focal cerebral
lesions in patients with AIDS.1 Current therapy for acute
cerebral toxoplasmosis is a combination of pyrimethamine plus
sulfadiazine.2 Alternative agents include clindamycin,
clarithromycin and azithromycin.3,4 In addition to the
significant adverse effect profile of the pryimethamine
combination, necessitating folinic acid replacement, none of
these agents is available in intravenous form in most public
service hospitals within the province of KwaZulu-Natal. The
combination of trimethoprim-sulfamethoxazole (co-
trimoxazole) has been shown to possess antitoxoplasmic
activity in vitro3 and in vivo.5,6 The latter study,6 a retrospective
appraisal of intravenous therapy, showed a favourable
outcome in 87% of treated patients. The aim of the present
study was to prospectively evaluate the efficacy of oral co-
trimoxazole in acute cerebral toxoplasmosis.
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Toxoplasma encephalitis is the commonest cause of
intracranial mass lesions in AIDS patients. Effective therapy
includes  pyrimethamine plus sulfadiazine, clindamycin
with pyrimethamine, and co-trimoxazole. This study
examines the efficacy of oral co-trimoxazole in 20 AIDS
patients with toxoplasmosis and seeks to confirm the
experience of Torre et al.
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Methods
HIV-positive patients referred to the neurology unit with
radiological lesions suggestive of toxoplasmosis (multiple
lesions with rim enhancement, basal ganglia location, extensive
surrounding oedema) were entered into the study. Computed
tomography (CT) scans were performed on admission, before
commencing therapy. Repeat scans were done 2 - 4 weeks later,
except when neurological deterioration necessitated an earlier
scan. Patients qualifying for entry into the study were treated
with trimethoprim-sulfamethoxazole (co-trimoxazole 80 mg
and 400 mg respectively). An induction dose of 2 tablets 4
times daily for 1 month was followed by 2 tablets 12-hourly for
life in the absence of antiretroviral therapy and a CD4 count
below 200 cells/µl. This dose is comparable with the
international literature which cites doses of 10 and 50
mg/kg/day of trimethoprim-sulfamethoxazole respectively.
Clinical improvement was taken to indicate diagnostic
accuracy. Non-responders were referred to the neurosurgeons
for a stereotactic biopsy. Patients who refused consent for a
biopsy were started on antituberculosis treatment with or
without dexamethasone. All non-responders were excluded
from further statistical analysis. Treatment efficacy was
ascertained by clinical and/or radiological improvement.
Serological tests included HIV enzyme-linked immunosorbent
assay (ELISA) and Toxoplasma gondii antibodies, while CD4 cell
counts were available in 7 patients. In the latter phase of the
study, magnetic resonance imaging (MRI) scans were also
done.
Results
Twenty patients completed the study.  There was an equal
number of male and female patients. The mean age at
presentation was 32 years. Hemiparesis was the commonest
presenting symptom (77%), followed by mental status changes
(62%) and seizures (23%). All patients were HIV-positive. CD4
counts were available for 7 patients. These ranged from 1
cell/µl to 78 cells/µl. T. gondii antibodies were positive in 8 of
20 patients. All patients showed complete or partial clinical and
radiological improvement (Figs 1a, b, 2a, b). The improvement
was sustained on the selected maintenance regimen of 2 tablets
12-hourly.  However, not all patients continue to attend for
follow-up so the long-term outcome remains speculative. No
significant cutaneous side-effects were noted in our study
group, although a few developed minor gastrointestinal upset. 
Discussion
This study establishes the efficacy of oral co-trimoxazole as
therapy for acute cerebral toxoplasmosis in the doses
described. This has significant utility in the public sector. It is
recommended that oral co-trimoxazole be implemented as
first-line therapy in cases of suspected cerebral toxoplasmosis.
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Fig. 1a. Pre-treatment contrast-enhanced CT scan showing a
hypodense lesion in the left basal ganglia with rim enhancement and
surrounding oedema, causing effacement of the third ventricle and
midline shift.
Fig. 1b. Post-treatment contrast-enhanced CT scan of the same
patient showing resolution of the oedema, decrease in contrast uptake
and residual hypodensity.
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A limitation of this study is that many of the non-responders
declined a biopsy and were treated empirically. Hence the
aetiology of these lesions remains hypothetical. It is therefore
unclear whether all non-responders have an alternative
diagnosis or whether there is a sub-group of cerebral
toxoplasmosis that is unresponsive to co-trimoxazole therapy. 
Conclusion
Oral co-trimoxazole is effective  for acute toxoplasma
encephalitis in doses of 2 tablets 4 times daily for 1 month
followed by 2 tablets twice daily as secondary prophylaxis for
life. Lifetime prophylactic therapy for toxoplasmosis would
only apply if patients are not receiving antiretroviral therapy
with the CD4 count being under 200 cells/µl.
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Fig. 2a. Pre-treatment T1 MRI scan showing hypodense lesion in the
left basal ganglia with mass effect and midline shift.
Fig. 2b. T2 MRI picture of the same area showing central
hypodensity and surrounding high signal.
